Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.
Hosted on MSN5d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Shares of Solid Biosciences (NASDAQ:SLDB) jumped ~88% in the premarket on Tuesday after the gene therapy developer reported ...
Truist Financial analyst Joon Lee maintained a Buy rating on Solid Biosciences (SLDB – Research Report) today. The company’s shares closed ...
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of ...
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing ...
Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback